Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The firm primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
How did BRSYF's recent EPS compare to expectations?
The most recent EPS for BrainsWay Ltd. is $0.26, beating expectations of $0.13.
How did BrainsWay Ltd. BRSYF's revenue perform in the last quarter?
BrainsWay Ltd. revenue for the last quarter is $0.26
What is the revenue estimate for BrainsWay Ltd.?
According to 3 of Wall street analyst, the revenue estimate of BrainsWay Ltd. range from $50.58M to $47.21M
What's the earning quality score for BrainsWay Ltd.?
BrainsWay Ltd. has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does BrainsWay Ltd. report earnings?
BrainsWay Ltd. next earnings report is expected in 2026-06-09
What are BrainsWay Ltd.'s expected earnings?
BrainsWay Ltd. expected earnings is $46.13M, according to wall-street analysts.
Did BrainsWay Ltd. beat earnings expectations?
BrainsWay Ltd. recent earnings of $47.19M beat expectations.